Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant neoplasm involving the bile duct
Biomarker and diagnostic research for bile duct cancer has been reported in the published literature.
42 clinical trials registered, 16 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 1 PHASE3, 13 PHASE2, 10 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04645160](https://clinicaltrials.gov/study/NCT04645160) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:53 PM UTC
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers |
PHASE1 |
National Cancer Institute (NCI) |
RECRUITING |
[NCT06175845](https://clinicaltrials.gov/study/NCT06175845) | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma | NA | Universitätsklinikum Hamburg-Eppendorf | RECRUITING |
[NCT06340620](https://clinicaltrials.gov/study/NCT06340620) | EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope | NA | Orlando Health, Inc. | RECRUITING |
[NCT03452774](https://clinicaltrials.gov/study/NCT03452774) | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | RECRUITING |
[NCT06274879](https://clinicaltrials.gov/study/NCT06274879) | Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer | PHASE2 | Insel Gruppe AG, University Hospital Bern | RECRUITING |
232 publications have been identified in PubMed for bile duct cancer. Kisho has analyzed 157 by research type. Research spans Epidemiology / Natural History (26%), Basic Science / Preclinical (25%), and Diagnostic / Biomarker (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 41 | 26% |
Laboratory research | 39 | 25% |
Testing and diagnosis research | 19 | 12% |
Research summaries | 17 | 11% |
Clinical study results | 16 | 10% |
Patient case studies | 15 | 10% |
New treatment approaches | 9 | 6% |
Other research | 1 | 1% |
Zhang H (2026). [PMID: 42094205](https://pubmed.ncbi.nlm.nih.gov/42094205/). *Front Oncol*. [Review / Meta-Analysis]
Kim JS (2026). [PMID: 41702441](https://pubmed.ncbi.nlm.nih.gov/41702441/). *Int J Radiat Oncol Biol Phys*. [Epidemiology / Natural History]
Choi GW (2026). [PMID: 42198859](https://pubmed.ncbi.nlm.nih.gov/42198859/). *Yonsei Med J*. [Diagnostic / Biomarker]
Kim M (2026). [PMID: 41928626](https://pubmed.ncbi.nlm.nih.gov/41928626/). *Clin Mol Hepatol*. [Clinical Trial Publication]
Miwa H (2026). [PMID: 40458535](https://pubmed.ncbi.nlm.nih.gov/40458535/). *DEN open*. [Basic Science / Preclinical]
Chaiyadet S (2026). [PMID: 40905941](https://pubmed.ncbi.nlm.nih.gov/40905941/). *J Infect Dis*. [Diagnostic / Biomarker]
Berg SW (2026). [PMID: 42137248](https://pubmed.ncbi.nlm.nih.gov/42137248/). *Front Gastroenterol (Lausanne)*. [Epidemiology / Natural History]
Yasukawa K (2026). [PMID: 41212458](https://pubmed.ncbi.nlm.nih.gov/41212458/). *Ann Surg Oncol*. [Review / Meta-Analysis]
Kaur RJ (2026). [PMID: 41639322](https://pubmed.ncbi.nlm.nih.gov/41639322/). *Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology*. [Epidemiology / Natural History]
Itano O (2026). [PMID: 41488837](https://pubmed.ncbi.nlm.nih.gov/41488837/). *Annals of gastroenterological surgery*. [Basic Science / Preclinical]